Skip to main content

Table 1 Tumour characteristics of the breast cancer specimens

From: TGFβ isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications

Cohorts

TCGA

TCGA-sub

RT-qPCR

Ivshina

Schmidt

Symmans

Wang

N

520

59

71

249

200

298

286

Histological type

 Ductal

442 (85.0)

51 (86.4)

56 (78.9)

 Lobular

41 (7.9)

3 (5.1)

5 (7.0)

 Mixed and others

36 (6.9)

5 (8.5)

9 (12.7)

Tumour diameter

 ≤2.0 cm

133 (25.6)

20 (33.9)

39 (54.9)

126 (50.6)

112 (56.0)

 >2.0 cm

364 (70.0)

38 (64.4)

32 (45.1)

123 (49.4)

88 (44.0)

Regional lymph nodes

 Negative

253 (48.7)

25 (42.4)

34 (47.9)

159 (63.9)

200 (100)

175 (58.7)

286 (100)

 Positive

256 (49.2)

34 (57.6)

36 (50.7)

81 (32.5)

0 (0)

112 (37.6)

0 (0)

Distant metastasis

 Negative

491 (94.4)

57 (96.6)

 Positive

15 (2.9)

1 (1.7)

TNM stage

 I

89 (17.1)

13 (22.0)

 II

290 (55.8)

34 (57.6)

 III

110 (21.2)

11 (18.6)

 IV

14 (2.7)

1 (1.7)

Tumour grade

 Grade 1

7 (9.9)

68 (27.3)

29 (14.5)

 Grade 2

25 (35.2)

126 (50.6)

136 (68.0)

 Grade 3

36 (50.7)

55 (22.1)

35 (17.5)

ER status

 Negative

117 (22.5)

9 (15.3)

18 (25.4)

34 (13.7)

0 (0)

77 (26.9)

 Positive

396 (76.2)

48 (81.4)

52 (73.2)

211 (84.7)

298 (100)

209 (73.1)

PR status

 Negative

176 (33.8)

16 (27.1)

22 (31.0)

 Positive

336 (64.6)

41 (69.5)

48 (67.6)

HER2 status

 Negative

361 (69.4)

48 (81.4)

60 (84.5)

 Positive

101 (19.4)

10 (16.9)

10 (14.1)

Triple-negative

 True

72 (13.8)

7 (11.9)

11 (15.5)

 False

448 (86.2)

52 (89.1)

60 (84.5)

PAM50 subtype

 Basal-like

96 (18.5)

11 (18.6)

 HER2-enriched

58 (11.2)

4 (6.8)

 Luminal A

231 (44.4)

32 (54.2)

 Luminal B

127 (24.4)

12 (20.3)

 Normal-like

8 (1.5)

0 (0)

  1. Data are presented as the number of patients in each subgroup with percentage in the parentheses. Numbers may not sum to total (N) due to missing datadata